1. Report Industry Investment Rating No relevant content provided. 2. Core View of the Report On November 28, 2025, the convertible bond market showed incremental growth and an increase in valuation. Small - cap growth stocks had an advantage in the market style, and the trading sentiment in the convertible bond market heated up. Most industries in the underlying stocks and convertible bonds rose [1]. 3. Summary by Relevant Catalogs 3.1 Market Main Index Performance - Index performance: The CSI Convertible Bond Index rose 0.68% month - on - month, the Shanghai Composite Index rose 0.34%, the Shenzhen Component Index rose 0.85%, the ChiNext Index rose 0.70%, the SSE 50 Index fell 0.09%, and the CSI 1000 Index rose 1.06%. From the perspective of style indices, small - cap growth stocks were relatively dominant, with small - cap growth rising 1.67% [1][7]. 3.2 Market Fund Performance - Trading volume: The trading volume of the convertible bond market was 5.9368 billion yuan, a month - on - month increase of 19.84%; the total trading volume of the Wind All - A Index was 159.7731 billion yuan, a month - on - month decrease of 7.28%. The net inflow of main funds in the Shanghai and Shenzhen stock markets was 682.5 million yuan, and the yield of the 10 - year treasury bond decreased by 1.25bp month - on - month to 1.84% [1][8]. 3.3 Convertible Bond Valuation - Bond price: The weighted average closing price of convertible bonds was 132.44 yuan, a 0.87% increase from the previous day. The proportion of high - price bonds above 130 yuan was 54.04%, a 2.28 - percentage - point increase from the previous day. The price median was 130.74 yuan, a 0.55% increase from the previous day [2]. - Valuation: The fitted conversion premium rate of 100 - yuan par value was 31.35%, a 0.44 - percentage - point increase from the previous day. The overall weighted par value was 100.04 yuan, a 0.91% increase from the previous day. The premium rates of all types of convertible bonds increased [2]. 3.4 Industry Rotation - Underlying stock industry: 28 industries in the A - share market rose, with the top three gainers being steel (+1.59%), agriculture, forestry, animal husbandry and fishery (+1.59%), and commerce and retail (+1.46%); only two industries fell, namely banking (-0.83%) and coal (-0.14%) [3]. - Convertible bond industry: All convertible bond industries rose, with the top three gainers being steel (+4.81%), building materials (+4.56%), and power equipment (+2.70%) [3]. - Different sectors: In terms of closing price, large - cycle rose 1.60%, manufacturing rose 1.28%, technology rose 0.62%, large - consumption rose 0.57%, and large - finance rose 0.32%. In terms of conversion premium rate, large - cycle decreased by 0.087 percentage points, manufacturing decreased by 0.3 percentage points, technology decreased by 0.36 percentage points, large - consumption increased by 0.016 percentage points, and large - finance increased by 1.3 percentage points [3].

Investment Rating - The report does not explicitly provide an investment rating for the blood purification device industry Core Insights - The report highlights the increasing prevalence of End-Stage Renal Disease (ESRD) globally and in China, with the number of patients expected to rise significantly by 2030, indicating a growing market for blood purification devices [13][15] - Blood purification is identified as the most widely used treatment method for ESRD, with a higher survival rate compared to other treatments like kidney transplantation and conservative treatment [19] - The Chinese blood purification device market is projected to grow rapidly, driven by an increase in ESRD patients, improved reimbursement policies, and advancements in dialysis infrastructure [26] Market Overview - The global ESRD patient population increased from 9.13 million in 2019 to 11.14 million in 2023, with a CAGR of 5.1%, and is expected to reach 14.85 million by 2030 [13][14] - In China, the ESRD patient population grew from 3.03 million in 2019 to 4.13 million in 2023, with a CAGR of 8.1%, projected to reach 6.13 million by 2030 [15] - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.07 million in 2023, with a CAGR of 9.8%, expected to reach 3.79 million by 2030 [19][18] Treatment Methods - Blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most common and effective method for ESRD patients [23] - Hemodialysis is noted for its effectiveness in removing toxins and excess fluid, while peritoneal dialysis is gaining traction due to its home treatment capabilities [21][23] Market Size and Growth - The Chinese blood purification device market size increased from 116.3 billion yuan in 2019 to 145.0 billion yuan in 2023, with a CAGR of 5.7%, and is expected to reach 515.2 billion yuan by 2030, with a projected CAGR of 19.9% from 2023 to 2030 [26] - The market for blood purification devices is segmented into blood purification machines, blood purification consumables, and other related equipment, with significant growth expected across all segments [26] Competitive Landscape - Domestic companies are rapidly catching up to international competitors in the blood purification consumables market, achieving nearly 50% market share in key areas [27] - The report indicates that the domestic market for blood purification machines still has room for growth, as these products have historically relied on imports due to high technical barriers [27][34] - The report emphasizes that domestic manufacturers are improving their technology and performance, positioning themselves to capture a larger market share [29][34]

Investment Rating - The report maintains a "Recommend" rating for the banking industry in Zhejiang Province, highlighting its strong potential due to the active private economy and favorable financial environment [2]. Core Insights - The banking sector in Zhejiang, particularly Hangzhou Bank, is positioned as a high-potential financial partner, benefiting from the region's economic vitality and robust growth in various financial services [3][8]. - The report emphasizes the resilience of Zhejiang's economy, with a GDP growth rate consistently above the national average, despite challenges such as trade friction [9][20]. - The analysis identifies several unlisted banks in Zhejiang as potential investment opportunities, focusing on their profitability, growth potential, and asset quality [8][9]. Summary by Sections 1. Overview of Zhejiang's Private Economy - Zhejiang's private economy reached 6.1 trillion yuan in 2024, accounting for 67.4% of the province's GDP, contributing over 70% of tax revenue and 80% of imports and exports [13][20]. - The province has a strong entrepreneurial culture, with a historical reliance on private economic forces due to limited state support [19][20]. 2. Economic Structure - The primary industries in Zhejiang are wholesale and retail, and manufacturing, with the service sector contributing approximately 60% to the GDP [26][30]. - The province's export dependency is significant, with over 40% of GDP derived from exports, and a notable reliance on the U.S. market [35][39]. 3. Banking Sector Characteristics - Zhejiang has a diverse banking landscape with 168 legal entities, including 13 city commercial banks and 82 rural commercial banks, primarily serving small and medium-sized enterprises [56][57]. - The report highlights the strong profitability and asset quality of listed city commercial banks like Hangzhou Bank and Ningbo Bank, which focus on different customer segments [57][59]. 4. Hidden Gems in Banking - The report identifies six unlisted city commercial banks and 25 rural commercial banks in Zhejiang with strong ROE and low non-performing loan ratios as potential investment targets [8][9][56]. 5. Investment Recommendations - Investors are encouraged to focus on the high-growth potential of banks in Zhejiang, particularly listed banks that may be undervalued, as well as exploring opportunities in unlisted banks [8][9].

Investment Rating - The report has downgraded the investment rating to "Recommended" [1][7][17] Core Views - Li Auto's Q3 2025 results showed a revenue of 27.4 billion yuan, down 36% year-on-year and 10% quarter-on-quarter, with a net profit loss of 620 million yuan, a decrease of 3.4 billion yuan year-on-year and 1.7 billion yuan quarter-on-quarter [1][7] - The decline in sales volume, which reached 93,000 units in Q3 2025, was primarily driven by the L series, reflecting a 39% year-on-year and 16% quarter-on-quarter drop [7][8] - The company is entering a new development phase, focusing on organizational, product, and technological advancements, with plans to upgrade its VLA architecture by the end of the year [7][8] Financial Summary - Total revenue projections for 2025 have been revised down from 130.2 billion yuan to 111.6 billion yuan, with net profit estimates adjusted from 5.7 billion yuan to 1.1 billion yuan [7][8] - The average selling price (ASP) for vehicles in Q3 2025 was 278,000 yuan, showing a slight increase compared to previous periods [7] - The gross margin for Q3 2025 was reported at 16.3%, down 5.2 percentage points year-on-year, primarily due to the MEGA recall, which is estimated to have impacted profits by approximately 1.1 billion yuan [7][8] Sales and Production Outlook - The launch of the Li Auto i6, priced from 249,800 yuan, has garnered over 70,000 orders, although production constraints limited October sales to 6,000 units [7][8] - The company plans to implement a dual-supplier model for i6 batteries starting in November, with expectations to ramp up production capacity to 20,000 units per month by early 2026 [7][8] Valuation and Price Target - The target price range for Li Auto is set between 81.27 and 97.52 HKD, reflecting a potential upside of 12% to 34% based on a relative valuation method [7][8]

Investment Rating - The report maintains a "Recommended" investment rating for the company with a target price of 56 yuan [2][8]. Core Insights - The company's core product categories have shown strong performance, with significant revenue growth driven by products such as respiratory machines, hearing aids, and home testing kits [8]. - The company is accelerating its overseas business expansion, supported by successful integration of recent acquisitions, which enhances its market presence and operational efficiency [8]. - The hearing aid business is gradually improving profitability, with a focus on enhancing the operational quality of existing stores [8]. Financial Performance Summary - For the first three quarters of 2025, the company reported total revenue of 2.398 billion yuan, a year-on-year increase of 6.63%, and a net profit attributable to shareholders of 260 million yuan, up 3.30% [2]. - In Q3 2025 alone, revenue reached 902 million yuan, reflecting a substantial growth of 30.72%, while net profit increased by 38.68% to 93 million yuan [2]. - The financial forecast indicates a steady growth trajectory, with projected revenues of 3.346 billion yuan in 2025, 3.890 billion yuan in 2026, and 4.556 billion yuan in 2027, representing year-on-year growth rates of 12.2%, 16.2%, and 17.1% respectively [4][9]. Market Position and Strategy - The company is strategically focusing on its core product categories to enhance sales and profitability, while also optimizing its product structure by phasing out less profitable items [8]. - The successful acquisition of Shanghai Huazhou and Hong Kong Ximan has strengthened the company's product offerings and market access, particularly in overseas markets [8]. - The introduction of advanced hearing aid technology, such as the new bone conduction hearing aid featuring Tencent's AI algorithm, is expected to improve product competitiveness and market share [8].

Investment Rating - The report maintains a "Recommendation" rating for Haier Biomedical (688139) with a target price of 44 yuan [2][8]. Core Insights - The company reported a slight decline in revenue for the first three quarters of 2025, with total revenue of 1.761 billion yuan, down 1.17% year-on-year, and a significant drop in net profit, down 35.83% to 198 million yuan [2][8]. - In Q3 2025, revenue showed a modest increase of 1.24% to 566 million yuan, while net profit decreased by 25.60% [2][8]. - The company is experiencing a recovery in Q3 2025, with a quarter-on-quarter revenue growth of 11.68% and a net profit growth of 71.34% compared to Q2 2025 [8]. Financial Performance Summary - For 2024A to 2027E, total revenue is projected to grow from 2.284 billion yuan in 2024 to 2.850 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 11.4% by 2027 [4][9]. - The net profit is expected to decline from 367 million yuan in 2024 to 259 million yuan in 2025, before recovering to 334 million yuan in 2027 [4][9]. - The earnings per share (EPS) is forecasted to decrease from 1.15 yuan in 2024 to 0.82 yuan in 2025, with a gradual recovery to 1.05 yuan by 2027 [4][9]. Business Segment Analysis - New industries accounted for approximately 48% of total revenue in the first three quarters of 2025, with significant growth in the smart medication and blood technology sectors [8]. - The overseas business generated 634 million yuan in revenue, reflecting a year-on-year growth of 20.18%, driven by local operations in 18 countries [8]. - Domestic revenue decreased by 10.48% year-on-year, but the decline has narrowed, with Q3 2025 showing stable performance [8]. Valuation and Future Outlook - The report estimates the company's net profit for 2025 to be 260 million yuan, with projections of 290 million yuan in 2026 and 330 million yuan in 2027, corresponding to price-to-earnings (PE) ratios of 40, 35, and 31 respectively [8][9]. - A discounted cash flow (DCF) model values the company at 141 billion yuan, supporting the target price of 44 yuan [8].

Overall Viewpoint - The core viewpoint of the report emphasizes that demand is the source of strength and innovation is the light that breaks the deadlock in the pharmaceutical industry. The continuous demand for pharmaceuticals and the increasing unmet needs drive pharmaceutical companies to invest in research and development, leading to explosive revenue and stock price growth [5][7][13]. Innovation Drugs - China has become a significant participant in global innovative drug research and development, with a high-quality growth rate of therapies in development far exceeding the global average. The domestic innovative drug sector is entering a revenue era driven by innovation, creating a positive dynamic between traditional pharmaceutical companies and emerging players [5][7][27]. - The number of domestic new drug overseas authorizations has surpassed $10 billion since 2021, indicating a sustained increase in overseas authorization activity, which continues to propel China's innovative drugs into the global market [5][7][27]. Pharmaceutical Industry - The report indicates that the innovative layout in the pharmaceutical industry is beginning to yield results, with performance expected to accelerate. Many companies are transitioning to a growth phase driven by innovation, suggesting that the current period is just the beginning of a more significant performance acceleration [5][7][27]. CXO Sector - Starting in the second half of 2024, global pharmaceutical research and development demand is expected to gradually recover, with strong demand for new molecular types such as peptides and ADCs driving growth in the CDMO segment. The value of leading CRO companies is anticipated to further highlight as the difficulty and barriers in drug development increase [5][7][27]. API Sector - The core business of API companies is primarily focused on non-U.S. exports (to Europe and India), with current demand remaining strong. Leading companies are achieving positive results in expanding into CDMO businesses, and many have integrated local market formulation businesses, which are expected to benefit from the easing of centralized procurement policies [5][7][27]. Medical Devices - The high-value consumables sector is experiencing a reduction in procurement pressure, with performance expected to return to a high growth trajectory. The report highlights that the bidding for medical devices is recovering, indicating an upcoming turning point for the sector, with optimism for domestic equipment technology upgrades and international expansion [5][7][27]. Traditional Chinese Medicine - The report expresses optimism for the recovery of the traditional Chinese medicine sector in 2026, with upward factors outweighing downward ones. The expected recovery sequence for sub-sectors includes hospital-based traditional Chinese medicine, four categories of drugs, OTC common drugs, and high-value consumer traditional Chinese medicine [5][7][27]. Medical Services - The report anticipates that with the introduction of several positive macro policies, consumer expectations are likely to recover. If favorable local fiscal policies are implemented, the bad debts and payment cycles for private hospitals will also see substantial relief, alleviating market concerns [5][7][27]. Pharmaceutical Retail - The pharmaceutical retail sector has faced continuous pressure since Q3 2024, primarily due to declining demand for four categories of drugs, consumption downgrading, intensified competition, and fluctuations in medical insurance policies. However, as high baselines are gradually digested, the revenue growth of leading chains is expected to stabilize and improve [5][7][27]. Blood Products - Despite short-term performance pressures, the essential nature of blood products indicates that supply and demand are expected to rebalance. The diversity of products among companies is rapidly increasing, with high-value new products like immunoglobulin expected to drive industry growth [5][7][27]. Life Sciences Services - The life sciences services sector is experiencing a demand recovery, coupled with deepening domestic substitution and ongoing overseas expansion, leading to a positive quarterly revenue growth starting from Q4 2024. The net profit margin of the sector has been gradually improving, indicating sustained profitability [5][7][27].

证 券 研 究 报 告 澳华内镜（688212）2025 年三季报点评 推荐（维持） 收入端拐点已至，新品 AQ-400 放量可期 事项： ❖ 公司发布 25 年三季报。25Q1-3，营业收入 4.23 亿元（-15.57%），归母净利润 -0.56 亿元（24 年同期 0.37 亿元），扣非净利润-0.68 亿元（24 年同期 0.15 亿 元）。25Q3，营业收入 1.62 亿元（+10.37%），归母净利润-0.15 亿元（24 年同 期 0.32 亿元），扣非净利润-0.16 亿元（24 年同期 0.16 亿元）。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 750 | 753 | 943 | 1,137 | | 同比增速(%) | 10.5% | 0.4% | 25.3% | 20.6% | | 归母净利润(百万) | 21 | 11 | 83 | 116 | | 同比增速(%) | -63.7% | -45.5% ...

Group 1 - The report maintains a positive outlook on offshore wind growth potential, while the value recovery of thermal, hydropower, and nuclear power is expected [2][10] - The overall performance of the power sector in 2025 is projected to lag behind the Shanghai Composite Index, with thermal power showing some performance release due to lower coal prices [5][12] - The report emphasizes the changing positioning of offshore wind in the 14th and 15th Five-Year Plans, indicating a potential growth inflection point due to a low current base [10][20] Group 2 - The report highlights the favorable policy environment and potential for valuation recovery in traditional green energy, particularly offshore wind, which is still in its early stages of development [6][21] - The traditional green energy sector is under pressure, but there are expectations for a pricing rebound as subsidy payments accelerate and outstanding issues are resolved [25][29] - The report notes that the valuation framework for green energy may undergo reconstruction, with a shift towards favoring companies with higher return on equity (ROE) [27][29] Group 3 - Thermal power is expected to transition from a cyclical to a utility-like asset, with long-term contract prices stabilizing and potential increases in capacity prices in 2026 [39][46] - The report identifies several thermal power companies, such as Jianneng Power and Huadian International, as having strong relative performance and dividend yields exceeding 5% [47][48] - The report anticipates that the market may reassess the value of hydropower and nuclear power assets, which have underperformed recently but are expected to regain attention as market conditions change [51][56] Group 4 - Hydropower and nuclear power are viewed as having long-term value recovery potential, with hydropower expected to return to a defensive allocation logic if market conditions shift [51][52] - The report indicates that nuclear power is experiencing a valuation reset due to stable growth expectations and the approval of new units, which could attract more investment if market risk appetite declines [56]

Core Insights - The report emphasizes the potential for improvement in the dry bulk shipping market, particularly for Capesize vessels, with freight rates expected to rise further based on the second half of 2025 [3][10] - The West Simandou iron ore project is highlighted as a key catalyst, expected to disrupt the current iron ore supply dominance of Australia and Brazil, with a projected increase in global iron ore demand by approximately 6.8% post full production [3][10] Shipping Industry Overview - The shipping industry is projected to experience a favorable supply-demand dynamic, with limited supply growth and potential demand increases due to various factors, including the West Simandou project and macroeconomic conditions [8][12] - The total market capitalization of the shipping sector is reported at 579.568 billion yuan, with a circulating market value of 458.746 billion yuan [4] Oil Shipping - The oil shipping sector is expected to benefit from a global oil production increase, sanctions improving demand structure, and supply constraints, leading to a sustained upward trend in market conditions [6][9] - VLCC freight rates have shown significant strength, with the TD3C route recording a rate of $126,000 per day on November 13, 2025, and an average rate of $104,000 per day for November [6][15] Dry Bulk Shipping - The dry bulk shipping market is recovering, with the BDI index averaging 1997 points, indicating a near five-year high, driven by improved demand for iron ore and coal [6][44] - Supply growth for dry bulk vessels is limited, with Capesize orders at only 9.32%, leading to projected capacity growth rates of 1.4%, 2.2%, and 2.6% for 2025-2027 [10][49] Container Shipping - The container shipping market in Asia remains tight, with a significant portion of new orders focused on ultra-large container ships, while smaller vessels face aging issues [11][68] - Despite a year-on-year decline in freight rates, the Asian container shipping market is expected to maintain demand above industry growth levels due to regional economic growth [11][68] Investment Recommendations - The report recommends investments in companies such as China Merchants Energy and COSCO Shipping Energy for oil shipping, and Haitong Development and China Merchants Industry for dry bulk shipping, citing favorable supply-demand dynamics [12][68] - For container shipping, it suggests focusing on Jinjiang Shipping and Zhonggu Logistics, while keeping an eye on Hapag-Lloyd International [12][68]